TNFRSF17 and plasma cell myeloma: This autologous CAR-T product targets BCMA and is approved for treating adult patients with relapsed or refractory multiple myeloma who have previously undergone at least three lines of therapy, including a proteasome inhibitor and an immunomodulatory agent.